Results of shareholder votes disclosed under 8-K Item 5.07.
NXP Semiconductors N.V. shareholders approved Approval of amended remuneration of non-executive directors at the 2026-06-10 meeting.
“9. Approval of the amended remuneration of the non-executive directors. For Against Abstain Broker Non-Votes 202,864,477 458,804 605,205 16,703,788”
NXP Semiconductors N.V. shareholders approved Re-appointment of E&Y Accountants B.V as independent auditor for FY2026 at the 2026-06-10 meeting.
“8. Re-appointment of E&Y Accountants B.V as independent auditor of the Company for the fiscal year ending December 31, 2026. For Against Abstain Broker Non-Votes 220,427,219 77,290 127,765 —”
NXP Semiconductors N.V. shareholders approved Authorization of the Board to cancel ordinary shares held or to be acquired at the 2026-06-10 meeting.
“7. Authorization of the Board to cancel ordinary shares held or to be acquired by the Company. For Against Abstain Broker Non-Votes 220,286,871 223,407 121,996 —”
NXP Semiconductors N.V. shareholders approved Authorization of the Board to repurchase ordinary shares at the 2026-06-10 meeting.
“6. Authorization of the Board to repurchase ordinary shares. For Against Abstain Broker Non-Votes 219,862,515 197,592 572,167 —”
NXP Semiconductors N.V. shareholders approved Authorization of the Board to restrict or exclude pre-emption rights at the 2026-06-10 meeting.
“5. Authorization of the Board to restrict or exclude pre-emption rights accruing in connection with an issue of shares or grant of rights. For Against Abstain Broker Non-Votes 215,526,006 4,980,383 125,885 —”
NXP Semiconductors N.V. shareholders approved Authorization of the Board to issue ordinary shares and grant rights at the 2026-06-10 meeting.
“4. Authorization of the Board to issue ordinary shares of the Company (“ordinary shares”) and grant rights to acquire ordinary shares. For Against Abstain Broker Non-Votes 220,004,296 529,131 98,847 —”
NXP Semiconductors N.V. shareholders approved Re-appointment of directors (slate of 10) at the 2026-06-10 meeting.
“3a. Re-appointment of Mr. Rafael Sotomayor as executive director with effect from June 10, 2026. For Against Abstain Broker Non-Votes 203,645,053 163,755 119,678 16,703,788”
NXP Semiconductors N.V. shareholders approved Granting discharge to the members of the Board for responsibilities in FY2025 at the 2026-06-10 meeting.
“2. Granting discharge to the members of the Company’s Board of Directors (the “Board”) for their responsibilities in the financial year ended December 31, 2025. For Against Abstain Broker Non-Votes 201,115,927 2,562,110 250,449 16,703,788”
NXP Semiconductors N.V. shareholders approved Adoption of the 2025 statutory annual accounts at the 2026-06-10 meeting.
“1. Adoption of the 2025 statutory annual accounts For Against Abstain Broker Non-Votes 203,646,857 37,095 244,534 16,703,788”
Trulieve Cannabis Corp. shareholders approved To ratify the selection of WithumSmith+Brown, PC as auditors for the Company for the year ending December 31, 2026 at the 2026-12-31 meeting.
“Proposal No. 4: To ratify the selection by the Audit Committee of the Board of WithumSmith+Brown, PC as auditors for the Company for the year ending December 31, 2026. The shareholders ratified the appointment of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the ensuing fiscal year ending December 31, 2026. Votes For Votes Against Abstain 107,441,983 1,169,382 676,220”
Trulieve Cannabis Corp. shareholders approved Advisory vote on the compensation of the Company’s named executive officers at the 2025-12-31 meeting.
“Proposal No. 3: To conduct a non-binding advisory vote on the compensation of the Company’s named executive officers. The shareholders approved the compensation paid to the Company’s named executive officers for the fiscal year ending December 31, 2025. Votes For Votes Against Abstain Broker Non-Votes 49,752,239 1,997,073 333,090 57,205,183”
Trulieve Cannabis Corp. shareholders approved To elect seven directors as directors of the Company for the forthcoming year.
“Proposal No. 2: To elect seven directors as directors of the Company for the forthcoming year. The shareholders voted to elect the following individuals as directors of the Company until the next annual meeting of shareholders at which election of directors is considered, or until his or her successor is duly elected or appointed:”
Trulieve Cannabis Corp. shareholders approved To set the number of directors of the Company at seven.
“Proposal No. 1: To set the number of directors of the Company at seven (7) Votes For Votes Against Abstain 107,646,420 1,235,766 405,399”
Rigetti Computing, Inc. shareholders approved Ratification of the Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“The Company’s stockholders ratified the appointment of BDO USA, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 185,103,270 1,473,228 1,452,171 —”
Rigetti Computing, Inc. shareholders approved Election of a Class I Director at the 2026-06-09 meeting.
“The Company’s stockholders elected the person listed below as a Class I Director to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows: Name Votes For Votes Withheld Broker Non-Votes Subodh Kulkarni 84,378,493 9,946,548 93,703,628”
Biomea Fusion, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
“Proposal 2 - Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2026.”
Biomea Fusion, Inc. shareholders approved Election of two Class II directors at the 2026-06-10 meeting.
“Proposal 1 - Election of Directors The Company’s stockholders elected the two (2) director nominees below to the Company’s Board of Directors as Class II directors to hold office until the 2029 Annual Meeting of Stockholders of the Company or until their successors are duly elected and qualified.”
Orthofix Medical Inc. shareholders approved Ratification of the Selection of Ernst & Young LLP at the 2026-06-10 meeting.
“Ratification of the Selection of Ernst & Young LLP. The selection of Ernst & Young LLP to act as the independent registered public accounting firm for the Company and its subsidiaries for the fiscal year ending December 31, 2026 was ratified by a vote of (i) 33,262,505 in favor, (ii) 1,384,292 against, and (iii) 129,879 abstaining.”
Orthofix Medical Inc. shareholders approved Advisory and Non-Binding Resolution to Approve Executive Compensation at the 2026-06-10 meeting.
“Advisory and Non-Binding Resolution to Approve Executive Compensation. The advisory and non-binding resolution to approve executive compensation was approved by a vote of (i) 24,480,474 in favor, (ii) 5,577,200 against, and (iii) 14,545 abstaining.”
Orthofix Medical Inc. shareholders approved Election of Board of Directors at the 2026-06-10 meeting.
“Election of Board of Directors. The following persons were elected as directors of the Company for a one-year term expiring at the 2027 Annual Meeting of Shareholders: Name Votes For Votes Against Abstentions Alan L. Bazaar 29,026,559 1,014,417 31,243 Wayne Burris 24,898,636 5,162,812 10,771 Massimo Calafiore 29,344,227 725,358 2,634 Vickie L. Capps 29,373,109 667,919 31,191 Michael M. Finegan 29,238,156 827,899 6,164 Jason M. Hannon 29,389,134 676,817 6,268 John B. Henneman, III 28,798,930 1,262,304 10,985 Charles R. Kummeth 28,990,854 1,070,316 11,049 Shweta S. Maniar 29,631,030 434,784 6,405 Michael E. Paolucci 24,698,858 5,367,249 6,112”
Cabaletta Bio, Inc. shareholders approved Adjournment proposal to permit further solicitation if needed for Charter Amendment Proposal at the 2026-06-09 meeting.
“Although Proposal 6 was deemed not necessary because there was a quorum present and there were sufficient proxies at the time of the Annual Meeting to approve the Charter Amendment Proposal, it was approved by the requisite vote as follows”
Cabaletta Bio, Inc. shareholders approved Non-binding advisory vote on compensation of named executive officers at the 2026-06-09 meeting.
“The Company's stockholders approved, by non-binding advisory vote, the compensation of the Company's named executive officers in Proposal 5.”
Cabaletta Bio, Inc. shareholders approved Amendment to Third Amended and Restated Certificate of Incorporation to increase authorized shares of common stock from 300,000,000 to 600,000,000 at the 2026-06-09 meeting.
“The Company’s stockholders approved the amendment to the Company's Third Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 600,000,000, recommended for approval as Proposal 4 at the Annual Meeting.”
Cabaletta Bio, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.
“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting.”
Cabaletta Bio, Inc. shareholders approved Election of two Class I directors, Scott Brun, M.D. and Shawn Tomasello, MBA at the 2026-06-09 meeting.
“The Company’s stockholders approved the Class I director nominees, Scott Brun, M.D. and Shawn Tomasello, MBA, recommended for election in Proposal 1 at the Annual Meeting.”
SHOE CARNIVAL INC shareholders approved Amendment to the Company's articles of incorporation to change the Company's name to Shoe Station Group, Inc. at the 2026-06-10 meeting.
“By the following vote, the shareholders approved the amendment to the Company's articles of incorporation to change the Company's name to Shoe Station Group, Inc.: For Against Abstain Broker Non-Votes 24,988,428 161,725 130,791 0”
SHOE CARNIVAL INC shareholders approved Ratification of appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal 2026 at the 2026-06-10 meeting.
“The appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal 2026 was ratified by the following shareholder vote: For Against Abstain Broker Non-Votes 25,071,774 152,109 57,061 0”
SHOE CARNIVAL INC shareholders approved Advisory (non-binding) vote on the compensation paid to the Company's named executive officers at the 2026-06-10 meeting.
“By the following vote, the shareholders approved the advisory (non-binding) vote on the compensation paid to the Company's named executive officers: For Against Abstain Broker Non-Votes 22,116,632 854,835 191,257 2,118,220”
SHOE CARNIVAL INC shareholders approved Election of directors to serve three-year terms expiring at the 2029 annual meeting at the 2026-06-10 meeting.
“The nominees for director were elected to serve three-year terms expiring at the 2029 annual meeting of shareholders and until their successors are elected and have qualified, as follows: Nominee For Against Abstain Broker Non-Votes Diane E. Randolph 20,690,085 2,467,029 5,610 2,118,220 J. Wayne Weaver 22,858,639 295,944 8,141 2,118,220”
TILLY'S, INC. shareholders approved Advisory vote to approve named executive officer compensation for fiscal year ended January 31, 2026 at the 2026-06-10 meeting.
“The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended January 31, 2026.”
TILLY'S, INC. shareholders approved Ratification of BDO USA, P.C. as independent registered public accounting firm for fiscal year ending January 30, 2027 at the 2026-06-10 meeting.
“The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending January 30, 2027.”
TILLY'S, INC. shareholders approved Approval of the Tilly's, Inc. Fourth Amendment and Restated 2012 Equity and Incentive Award Plan at the 2026-06-10 meeting.
“The Company's stockholders approved the Plan.”
TILLY'S, INC. shareholders approved Election of seven directors for a term expiring at 2027 annual meeting at the 2026-06-10 meeting.
“The Company's stockholders elected the following seven directors for a term of office expiring at the Company's 2027 annual meeting of its stockholders and until their successors are duly elected and qualified.”
Kennedy-Wilson Holdings, Inc. shareholders approved Adjournment proposal at the 2026-06-10 meeting.
“The Company’s stockholders approved the Adjournment Proposal, as follows: Votes For Votes Against Abstentions 143,306,344 6,169,767 76,065”
Kennedy-Wilson Holdings, Inc. shareholders approved Advisory compensation proposal to approve compensation payable to named executive officers in connection with the Merger Agreement at the 2026-06-10 meeting.
“The Company’s stockholders approved, on a non-binding, advisory basis, the Advisory Compensation Proposal as follows: Votes For Votes Against Abstentions 139,504,118 9,411,306 636,752”
Kennedy-Wilson Holdings, Inc. shareholders approved Proposal to adopt the Merger Agreement at the 2026-06-10 meeting.
“The Company’s stockholders approved the Merger Proposal, as follows: Majority Approval: Votes For Votes Against Abstentions 148,957,598 535,978 58,600”
KIORA PHARMACEUTICALS INC shareholders approved Approval of the amendment of the 2024 Equity Incentive Plan to increase the maximum number of shares authorized for issuance by 1,500,000 shares at the 2026-06-10 meeting.
“The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 732,106 311,987 1,576 1,320,660”
KIORA PHARMACEUTICALS INC shareholders approved Ratification of the appointment of Haskell & White LLP as the Company’s independent registered public accounting firm for fiscal year 2026 at the 2026-06-10 meeting.
“The results of the vote were as follows: Votes For Votes Against Votes Abstained 2,358,943 5,403 1,983”
KIORA PHARMACEUTICALS INC shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.
“The results of the vote were as follows: Votes For Votes Against Votes Abstained Broker Non-Votes 1,019,325 21,670 4,674 1,320,660”
KIORA PHARMACEUTICALS INC shareholders approved Election of Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle as Class II Directors at the 2026-06-10 meeting.
“The results of the election were as follows: Name Votes For Votes Withheld Broker Non-Votes Lisa Walters-Hoffert 1,037,950 7,719 1,320,660 Aron Shapiro 1,030,543 15,126 1,320,660 Praveen Tyle, Ph.D. 1,029,403 16,266 1,320,660”
EquipmentShare.com Inc shareholders approved Non-binding advisory approval of frequency of future votes on compensation of named executive officers at the 2026-06-04 meeting.
“Proposal No. 4 : to approve, on a non-binding and advisory basis, the frequency of future votes to approve the compensation of the Company’s named executive officers.”
EquipmentShare.com Inc shareholders approved Non-binding advisory approval of compensation of named executive officers at the 2026-06-04 meeting.
“Proposal No. 3 : to approve, on a non-binding and advisory basis, the compensation of the Company’s named executive officers.”
EquipmentShare.com Inc shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal No. 2 : to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
EquipmentShare.com Inc shareholders approved Election of nominees for director to serve until the 2027 annual meeting at the 2026-06-04 meeting.
“Proposal No. 1 : to elect the nominees for director to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.”
TERAWULF INC. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for 2026 at the 2026-06-09 meeting.
“The voting results were as follows: For Against Abstain Broker Non-Votes 346,591,072 610,441 1,144,008 0”
TERAWULF INC. shareholders approved Non-binding advisory vote on executive compensation at the 2026-06-09 meeting.
“The voting results were as follows: For Against Abstain Broker Non-Votes 179,761,319 92,319,915 1,258,505 75,005,782”
TERAWULF INC. shareholders approved Election of nine directors at the 2026-06-09 meeting.
“The voting results for each of the nominees were as follows: For Withhold Broker Non-Votes Paul Prager 269,921,879 3,417,860 75,005,782 Nazar Khan 270,937,776 2,401,963 75,005,782 Kerri Langlais 269,529,468 3,810,271 75,005,782 Michael Bucella 264,094,637 9,245,102 75,005,782 Walter Carter 270,382,268 2,957,471 75,005,782 Amanda Fabiano 271,969,893 1,369,846 75,005,782 Catherine Motz 259,703,960 13,635,779 75,005,782 Steven Pincus 251,989,771 21,349,968 75,005,782 Lisa Prager 257,630,363 15,709,376 75,005,782”
ImmunityBio, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.
“2. Ratification of Appointment of Independent Registered Public Accounting Firm. The appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by our stockholders based on the following results of voting: Votes “For” Votes “Against” Abstentions “Broker Non-Votes” 882,420,139 1,675,960 1,070,960 —”
ImmunityBio, Inc. shareholders approved Election of Nine Directors at the 2026-06-09 meeting.
“1. Election of Nine Directors. The following nominees were re-elected by the holders of our Common Stock to serve as directors for a one year term expiring at the 2027 annual meeting of stockholders based on the following results of voting. Each director's term continues until the election and qualification of his or her successor, or until his or her earlier retirement, resignation, disqualification, removal, or death. Nominee Votes “For” Votes “Withheld” “Broker Non-Votes” Patrick Soon-Shiong, M.D. 714,631,732 19,014,153 151,521,174 Cheryl L. Cohen 731,554,649 2,091,236 151,521,174 Richard Adcock 731,960,821 1,685,064 151,521,174 Michael D. Blaszyk 722,575,150 11,070,735 151,521,174 Wesley Clark 729,527,285 4,118,600 151,521,174 Linda Maxwell, M.D. 717,976,024 15,669,861 151,521,174 Christobel Selecky 722,387,537 11,258,348 151,521,174 Barry J. Simon, M.D. 731,770,436 1,875,449 151,521,174 Bruce Wendel 732,149,734 1,496,151 151,521,174”
Rocket Companies, Inc. shareholders approved Approval of amendment to Amended and Restated Rocket Companies, Inc. 2020 Team Member Stock Purchase Plan (TMSPP) to increase authorized shares available for purchase at the 2026-06-10 meeting.
“Approved an amendment to the Amended and Restated Rocket Companies, Inc. 2020 Team Member Stock Purchase Plan (the “ TMSPP ”) to increase the number of authorized shares available for purchase under the TMSPP”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.